NCT03536780View on ClinicalTrials.gov

Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

PHASE2UnknownINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Leiomyosarcoma Metastatic
Interventions
DRUG

Avelumab and Gemcitabine

"* Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"

Trial Locations (6)

Unknown

RECRUITING

Dong-a University Hospital, Busan

RECRUITING

Gachon University Gil Medical Center, Incheon

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

collaborator

Chong Kun Dang Pharmaceutical Corp.

INDUSTRY

lead

Gachon University Gil Medical Center

OTHER

NCT03536780 - Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment | Biotech Hunter | Biotech Hunter